Table 4.
Multivariate analysis (Cox regression model) of factors associated with OS and PFS.
| BRPA | LAPA | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall survival (n = 101) | Progression-free survival (n = 99) | Overall survival (n = 210) | Progression-free survival (n = 210) | |||||||||
| HR | 95% CI | p | HR | 95% CI | p | HR | 95% CI | p | HR | 95% CI | p | |
| Local involvement | ||||||||||||
| Arterial alone | 1 | — | 0.0002 | 1 | — | 0.03 | ||||||
| Venous alone | 2.33 | 1.53–3.56 | 1.52 | 1.05–2.21 | ||||||||
| Arterial and venous | 1.10 | 0.68–1.76 | 0.90 | 0.60–1.37 | ||||||||
| Biliary stent (yes vs no) | 1.36 | 0.93–2.00 | 0.11 | 1.19 | 0.86–1.65 | 0.29 | ||||||
| Tumour location | ||||||||||||
| Body | 1 | 0.02 | 1 | 0.11 | ||||||||
| Head | 0.33 | 0.15–0.70 | 0.57 | 0.31–1.08 | ||||||||
| Tail | 0.39 | 0.10–1.51 | 0.33 | 0.09–1.18 | ||||||||
| Performance status | ||||||||||||
| 0 | 1 | 1 | 1 | 1 | ||||||||
| 1 | 0.82 | 0.40–1.68 | 0.61 | 1.13 | 0.65–1.96 | 0.78 | 1.23 | 0.84–1.81 | 0.04 | 1.11 | 0.79–1.55 | 0.23 |
| 2 | 1.53 | 0.42–5.58 | 1.52 | 0.44–5.30 | 2.87 | 1.25–6.57 | 1.88 | 0.91–3.90 | ||||
| Type of treatment | ||||||||||||
| Chemo alone | 1 | 1 | 1 | 1 | ||||||||
| Chemo and CRT | 0.59 | 0.26–1.37 | 0.01 | 0.63 | 0.33–1.17 | 0.001 | 0.41 | 0.28–0.61 | <0.0001 | 0.47 | 0.33–0.67 | <0.0001 |
| Chemo +/− RT and secondary resection | 0.26 | 0.11–0.63 | 0.32 | 0.18–0.60 | 0.21 | 0.11–0.41 | 0.21 | 0.12–0.36 | ||||
BRPA borderline resectable pancreatic adenocarcinoma, LAPA locally advanced pancreatic adenocarcinoma, HR hazard ratio, 95% CI 95% confidence interval, CRT chemoradiation therapy.